

Increasing strength to the intellectual property in Bio-light's cancer diagnostics cluster

ZetiQ, a subsidiary of Micromedic, receives patent approval in Japan

for its cell staining technology designed to detect cancer cells

Bio-light holds about 25.46% shares in Micromedic, which holds 100% of ZetiQ shares

Tel Aviv, Israel, October 3 2012: Micromedic, a development and commercialization company engaged in creating value through a cluster of companies developing novel cancer diagnostics products, reported this morning that ZetiQ, a subsidiary of Micromedic, which is part of the company's cancer diagnostics cluster, was granted an umbrella patent in **Japan** for its cell-staining technology, CellDetect[®], designed for the detection and diagnosis of cancer cells.

Dr. Adi Elkeles, CTO & CBDO of the cluster, and former CEO of ZetiQ states: "the approval in **Japan** follows a similar approval we received in the U.S. two months ago, and is an important addition in protecting the company's intellectual property. This patent provides comprehensive protection to ZetiQ's platform technology, CellDetect[®], which offers differential cell staining for multiple cancer indications, enabling the company to develop additional applications beyond those to which ZetiQ is facing today. We believe that the technology and its inherent intellectual property offer significant benefits reflected in increased accuracy of detecting cancer cells, improving the process of identifying cancer cells, and reducing process costs".

In the frame of the announcement ZetiQ received, the patent eligibility approved in **Japan** is entitled METHODS AND COMPOSITIONS FOR IDENTIFYING A CELL PHENOTYPE (Application No.2008-557895).

The patent relates to the "CellDetect[®]" technology developed by ZetiQ, which is designed to allow a distinction between specific cell populations using a unique stain. This technology can offer tests for detecting cancer by diagnosing the cancer cells, and also to track disease recurrence in patients with cancer following treatment. As mentioned, the patent approved is an "umbrella" patent, which covers the multiple uses for the CellDetect[®] technology.

About Bio-light:

Bio-light life sciences investments in Israel Ltd., is a holding and management company, which through its subsidiaries, deals with building and managing clusters of companies in defined areas, through investing in companies engaged in research and development of pharmaceuticals and medical products. Established in 2005, in April 2011 a group of investors headed by Mr. Israel Makov acquired control of the company and introduced a new strategy of creating value through knowledge sharing (the cluster approach).

Bio-light operates its unique cluster business model in the biomedical field, creating value through synergies resulting from the sharing of knowledge between companies that treat common areas and tangents. The model is based on a combination of activities dealing with one disease from different directions: drugs, medical devices, molecular diagnostics, imaging, and more, all under a defined cluster of companies. Such cooperation can create added value by creating a knowledge base and experience which would provide a comprehensive familiarity with the disease, the market, the competition and leading the field, and produce unique solutions and innovation, which will be attractive to the signing of cooperation agreements with leading strategic partners.

For more information please visit: www.bio-light.co.il

About Micromedic:

Micromedic is a company engaged in the research, development, investment, commercialization and management of a cluster of companies in the diagnostics of cancer-related diseases, including by developing and commercializing markers and molecules based on different genes, mainly through subsidiaries. Micromedic is a public company, and Bio-light holds - 25.46% of the issued and outstanding shares of Micromedic, while Micromedic owns 100% of the equity of Zetiq.

For more information please visit: www.m-medic.com

About Zetiq:

Zetiq develops products for the detection and diagnosis of cancer, based on its unique CellDetect[®] technology, which allows diagnosis, based on differential coloring alongside morphological identification of cancer pre-cancerous cells. CellDetect[®] technology also allows the detection of cancer cells that appear less frequently in a very large population of cancer cells. In addition, the technology allows the detection of various cancers. These unique features enable the development of a variety of technology-based products to diagnose different cancers and different applications in clinical pathology. The competitive pricing of the company products, alongside the benefits of using these products, increase the potential for broad market penetration in the clinical pathology market.

The portfolio of the company's products is directed to the clinical pathology market, valued to be over \$ 13 billion in the US alone. Zetiq demonstrated the feasibility for early detection of cervical cancer cells and the detection of bladder cancer cells, and is promoting the company's plans to develop tools to diagnose these diseases.

For more information please visit: www.zetiq.co.il